A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose combination of Fenofibrate 160 mg and Pravastatin 40 mg (PRAVAFENIX) versus Atorvastatin 20 mg.

Trial Profile

A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose combination of Fenofibrate 160 mg and Pravastatin 40 mg (PRAVAFENIX) versus Atorvastatin 20 mg.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2015

At a glance

  • Drugs Fenofibrate/pravastatin (Primary) ; Atorvastatin
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Acronyms PART
  • Sponsors SMB
  • Most Recent Events

    • 28 Mar 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top